Skip to main content
. 2017 Jan 17;12(1):e0163509. doi: 10.1371/journal.pone.0163509

Fig 6.

Fig 6

Model predicted annual number* of cancer cases (a), cancer deaths (b), colposcopies (c) and precancer treatments (d) for unvaccinated cohorts (diamond) and cohorts offered vaccination (squares) under three strategies–current practice, primary HPV screening in which women testing OHR HPV and ASC-US/LSIL are referred for 12-month follow-up, and primary HPV screening in which this group is referred for 12- and 24-month follow-up.** *Case numbers derived by applying predicted age-specific rates to the projected Australian female population for 2017.[63]** Numbers in parentheses represent the difference in case numbers and percentage difference compared to the pre-renewed NCSP.